A studio service
LSI Emerging Medtech Summit decks where the buyer might be the acquirer.
Next: 15–19 March 2027, Dana Point, California. Companies pay for their slot on that stage, and present to a room holding medtech VCs, growth funds and the corporate development teams of the strategics who might one day buy them. That double audience is what makes the deck hard: it has to be an investment case and an acquisition case at once.
Investment
Three ways to raise.
Fixed price, fixed scope. Pick the tier that matches your raise — from a single deal deck to a full capital-raise kit.
Essential
A focused deck for a single asset or a partnering round - you bring the data, we design it.
5-7 business days
- 12-15 designed slides
- Pipeline table and mechanism diagram
- Data figures redrawn to publication standard
- Every claim footnoted to your source
- 1 revision round
- Editable PowerPoint source files
Standard
The full raise or partnering push: we shape the narrative, build the figures and cut the short version.
Priority - 4-5 business days
- 18-25 designed slides
- We build the narrative from your inputs
- Full figure set - efficacy, safety, IP timeline
- Non-confidential partnering version
- 2 revision rounds
- Editable PowerPoint + source files
Complete
Everything a conference season needs - deck, appendix, one-pager and the data-room set.
Rush available
- 30-50 slides - deck plus appendix
- Company presentation and partnering versions
- Non-confidential one-pager for the leave-behind
- Data-room slide set
- 3 revision rounds, white-glove
- 60-minute strategy call + all source files
N° 01What medtech decks must carry
Four things a device investor checks.
01
The regulatory pathway, named
510(k), De Novo, PMA, CE mark under MDR — which one, what stage, and what the next clearance actually unlocks. Vagueness here is read as not knowing, and it is the first thing a device investor looks for.
02
Reimbursement, not just approval
Clearance is permission to sell; coding and coverage are permission to get paid. A deck that stops at regulatory has answered half the question, and the half that matters less to the economics.
03
Manufacturing and unit economics
Cost per unit at volume, the supply chain behind it, and what gross margin looks like at scale. Devices live or die on this and it is routinely relegated to an appendix.
04
Who the acquirer would be
Corporate development teams from the strategics are in the room. The slide that shows where this fits inside a portfolio is not presumptuous — it is the question they came to answer.
N° 02What we build
The stage deck and the table deck.
01
The timed stage presentation
Projected, one-to-many, built to the clock. Big type, one idea per slide, and the evidence you most want remembered made the largest thing on it.
02
The partnering deck
Read on a laptop across a table, entered wherever their first question lands, with an appendix reachable in one click.
03
The strategic one-pager
For the corporate development reader who takes it back to a portfolio review you are not in the room for.
04
The evidence appendix
Clinical data, regulatory correspondence, detailed IP and manufacturing. Indexed rather than sequential, so a good question gets a fast answer.
N° 03Who this is for
Device, diagnostics, digital health.
01
Pre-revenue device companies raising Series A–C
Where clinical evidence and the next regulatory milestone carry the story, because revenue cannot yet.
02
Diagnostics companies
Where the analytical and clinical validation story, and the route to a payer, are the investment case.
03
Digital health with a regulated component
Software as a medical device sits between two worlds. The deck has to satisfy a device investor and a software investor without confusing either.
Sample slides
Sample slides, in house style.
Generated in our editorial discipline — framed to your vertical. Every deck we ship is original and bespoke.
Questions
The answers we give most often.
- What makes a medtech deck different from a biotech one?
- Regulatory pathway and reimbursement carry the weight clinical data carries in therapeutics. A device investor wants the pathway, the coding and coverage route, manufacturing unit economics, and who the strategic acquirer would be.
- Who is actually in the room?
- Medtech VCs and growth funds, family offices, and corporate development from the large strategics. That last group changes the deck — you are presenting to a potential acquirer as well as an investor.
- How long is the stage presentation?
- A timed slot, short enough that the discipline is subtraction. Companies pay to be on that stage, which is why building the deck the week before is an expensive way to waste it.
- Do we need a separate partnering deck?
- Usually yes. The stage deck is projected and one-to-many; the partnering deck is read on a laptop and driven by their questions. Same source of truth, different structure.
- We are pre-revenue. Does that change the deck?
- It changes what carries it — clinical evidence, the next regulatory milestone, and a credible reimbursement thesis. Pretending otherwise is transparent to an audience that prices risk for a living.
- Do you work on other life-sciences conferences?
- Yes — JPM week, Biotech Showcase, BIO-Europe and BIO International. A deck built once can be cut for each.
Next step
Presenting at LSI?
Tell us the device, where you are on the regulatory path, and whether you have a stage slot as well as partnering meetings. We'll come back with what we'd build and an honest read on the timeline.